Cover Image
市場調查報告書

肺癌治療藥的全球市場:調查與分析

Global Lung Cancer Therapeutic Market Research and Analysis, 2015-2021

出版商 Orion Market Research Pvt Ltd 商品編碼 545487
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
肺癌治療藥的全球市場:調查與分析 Global Lung Cancer Therapeutic Market Research and Analysis, 2015-2021
出版日期: 2017年02月18日 內容資訊: 英文
簡介

本報告提供肺癌治療藥的全球市場調查,提供整體市場趨勢,各治療藥·地區別的詳細趨勢,提供著治療藥的開發平台分析,已通過核准新藥概要,法規環境,市場促進·阻礙因素以及市場機會分析,競爭情形,主要企業簡介等,有系統的資訊。

第1章 報告主旨

第2章 市場概要

  • 市場定義
  • 開發平台分析
  • 分析師的見解
    • 主要的觀察
    • 建議
    • 總論
  • 法規環境
    • 美國
    • EU
    • 中國
    • 印度
    • 其他
  • 開發平台分析
    • Pembrolizumab
    • Atezolizumab
    • RG6016
    • Trastuzumab EMTANSINE
    • RG7604
    • Alectinib
    • 其他
  • 已通過核准新藥
    • ALECENSA (ALECTINIB), ROCHE
    • KEYTRUDA (PEMBROLIZUMAB), MERCK
    • OPDIVO (NIVOLUMAB), BRISTOL-MYERS SQUIBB
    • PORTRAZZA (NECITUMUMAB), ELI LILLY
    • TAGRISSO (OSIMERTINIB), ASTRAZENECA
    • ABITREXATE (METHOTREXATE)
    • AVASTIN (BEVACIZUMAB)
    • DOCETAXEL

第3章 市場決策要素

  • 推動因素
  • 阻礙因素
  • 市場機會

第4章 市場區隔

  • 肺癌治療藥市場分析
    • PLATINOL
    • TAXOL
    • GEMZAR
    • ALIMTA
    • IRESSA
    • HYCAMTIN
    • GILOTRIF
    • TAXOTERE
    • XALKORI
    • NAVELBINE
    • AVASTIN
    • TARCEVA
    • 其他

第5章 競爭分析

  • 主要策略
  • 主要企業分析

第6章 地區分析

  • 北美
  • 歐洲
  • 亞太地區
  • 其他

第7章 企業簡介

目錄
Product Code: PH-1310

The Global Lung Cancer Therapeutic Market is expected to grow at the CAGR of 13.2 % during 2016-2021. The Global Lung Cancer Therapeutic Market is growing at a modest rate due to rise in incidence prevalence rate of Lung cancer across the globe. The adoption of lung cancer drugs and innovative lung surgeries are expected to boost the global lung cancer market. Huge demand is created by rising diagnostic centers across the globe. Investment and grants from government and private players are driving the market. Successful clinical trials and FDA approval are the key factors creating huge scope in Global Lung Cancer Therapeutic Market. Adoption of Lung Cancer Therapeutic Market drugs such as Platinol, Taxol, Gemzar, Alimta, Iressa, Xalkori & Tarceva is increasing. Personalized medicines and drug discovery & development has significant contribution in the growth of Lung Cancer Therapeutic Market.

Geographical Insights:

North America and Europe has a considerable contribution to the growth of Global Lung Cancer Therapeutic Market followed by APAC region. The key driving forces include rising incidence of lung cancer Diseases and adoption of lung cancer drugs and surgeries across the globe. Emerging economies such as China, India, Japan, and Korea have most lung cancer patients and with improved healthcare system and healthcare spending APAC region looks promising for Global Lung Cancer Therapeutic Market. Improved standard of living, infrastructural development and favorable government policies are some other factors that will boost the APAC market. The report includes detailed Market Overview, Market Determinants, Company Profiling, Sector Analysis, Market Segmentation, Geographical Analysis, Pipeline Analysis, Patent Analysis, Strategic Recommendations, Key Company Analysis, Key Findings, Analyst Insights and predictive analysis of the market.

Competitive Insights:

The Global Lung Cancer Therapeutic Market companies include Boehringer Ingelheim, Abbvie, Eli Lilly, F. Hoffmann-La Roche GlaxoSmithKline, Merck Serono and Novartis. Lung Cancer Therapeutic companies are constantly focusing on R&D, partnerships, M&A, innovation and technological advancement.

Market Segmentation:

Global Lung Cancer Therapeutic Market Research And Analysis

Platinol

Taxol

Gemzar

Alimta

Iressa

Hycamtin

Gilotrif

Taxotere

Xalkori

Navelbine

Avastin

Tarceva

Others

OMR Report covers:

Comprehensive research methodology of Global Lung Cancer Market.

This report also includes detailed and extensive market overview with historical analysis & key analysts insights.

An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.

Analysis of regional regulations and other government policies impacting the Global Lung Cancer Market.

Insights about market determinants which are stimulating the Global Lung Cancer Market.

Detailed and extensive market segments with regional distribution of forecasted revenues.

Extensive profiles and recent developments of market players.

Table of Contents

REPORT SUMMARY

  • 1.1. RESEARCH METHODS AND TOOLS
  • 1.2. MARKET BREAKDOWN
    • 1.2.1. BY SEGMENTS
    • 1.2.2. BY GEOGRAPHY
    • 1.2.3. BY STAKEHOLDERS
    • 1.2.4. EXCEPTIONS

MARKET OVERVIEW AND INSIGHTS

  • 2.1. DEFINITION
  • 2.2. PIPELINE ANALYSIS
  • 2.3. ANALYST INSIGHT
    • 2.3.1. KEY FINDINGS & CURRENT MARKET TRENDS
    • 2.3.2. RECOMMENDATION
    • 2.3.3. CONCLUSION
  • 2.4. REGULATION
    • 2.4.1. UNITED STATES
    • 2.4.2. EUROPEAN UNION
    • 2.4.3. CHINA
    • 2.4.4. INDIA
    • 2.4.5. REST OF THE WORLD
  • 2.5. PIPELINE ANALYSIS
    • 2.5.1. KEYTRUDA MK-3475 NON-SMALL CELL LUNG CANCER DRUG
    • 2.5.2. ATEZOLIZUMAB (ANTI-PDL1, RG7446, MPDL3280A) ROCHE
    • 2.5.3. RG6016 (ROCHE)
    • 2.5.4. TRASTUZUMAB EMTANSINE (T-DM1)
    • 2.5.5. RG7604 PIK3CA
    • 2.5.6. ALECTINIB (RG7853)
    • 2.5.7. OTHERS
  • 2.6. NEWLY APPROVED DRUGS
    • 2.6.1. ALECENSA (ALECTINIB), ROCHE
    • 2.6.2. KEYTRUDA (PEMBROLIZUMAB), MERCK
    • 2.6.3. OPDIVO (NIVOLUMAB), BRISTOL-MYERS SQUIBB
    • 2.6.4. PORTRAZZA (NECITUMUMAB), ELI LILLY
    • 2.6.5. TAGRISSO (OSIMERTINIB), ASTRAZENECA
    • 2.6.6. ABITREXATE (METHOTREXATE)
    • 2.6.7. AVASTIN (BEVACIZUMAB)
    • 2.6.8. DOCETAXEL
    • 2.6.9. FOLEX (METHOTREXATE)
    • 2.6.10. OTHERS

MARKET DETERMINANT

  • 3.1. MOTIVATORS
    • 3.1.1. RISE IN INCIDENCE & PREVALENCE RATE OF CANCER DISEASES
    • 3.1.2. RISE IN INVESTMENT AND GRANTS FROM GOVERNMENT AND PRIVATE PLAYERS
    • 3.1.3. RISE IN DIAGNOSTIC CENTERS ACROSS THE GLOBE
    • 3.1.4. GROWTH IN PHARMACEUTICAL MARKET OF LUNG CANCER
    • 3.1.5. RESEARCH & DEVELOPMENT IN LUNG CANCER MARKET
    • 3.1.6. ADOPTION OF INNOVATIVE LUNG SURGERY
    • 3.1.7. FDA CLEARANCE TO LUNG CANCER DRUGS
    • 3.1.8. RISE IN ADOPTION OF PERSONALIZED MEDICINES
    • 3.1.9. RISING MORTALITY RATE DUE TO LUNG CANCER
  • 3.2. RESTRAINT
    • 3.2.1. HIGH COST OF GLOBAL LUNG CANCER DRUGS AND SURGERIES
    • 3.2.2. REIMBURSEMENT POLICIES MAY AFFECT THE GROWTH OF THE MARKET
  • 3.3. OPPORTUNITY
    • 3.3.1. UNTAPPED APAC REGION HAVE HUGE OPPORTUNITY FOR GLOBAL LUNG CANCER MARKET
    • 3.3.2. SUCCESSFUL CLINICAL TRIALS AND FDA APPROVALS

MARKET SEGMENTATION

  • 4.1. LUNG CANCER DRUGS MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
    • 4.1.1. PLATINOL
    • 4.1.2. TAXOL
    • 4.1.3. GEMZAR
    • 4.1.4. ALIMTA
    • 4.1.5. IRESSA
    • 4.1.6. HYCAMTIN
    • 4.1.7. GILOTRIF
    • 4.1.8. TAXOTERE
    • 4.1.9. XALKORI
    • 4.1.10. NAVELBINE
    • 4.1.11. AVASTIN
    • 4.1.12. TARCEVA
    • 4.1.13. OTHERS

COMPETITIVE LANDSCAPE

  • 5.1. KEY STRATEGIES
  • 5.2. KEY COMPANY ANALYSIS

REGIONAL ANALYSIS

  • 6.1. NORTH AMERICA
    • 6.1.1. UNITED STATES
    • 6.1.2. CANADA
    • 6.1.3. REST OF NORTH AMERICA
  • 6.2. EUROPE
    • 6.2.1. UK
    • 6.2.2. GERMANY
    • 6.2.3. SPAIN
    • 6.2.4. FRANCE
    • 6.2.5. ITALY
    • 6.2.6. REST OF EUROPE
  • 6.3. ASIA PACIFIC
    • 6.3.1. INDIA
    • 6.3.2. CHINA
    • 6.3.3. JAPAN
    • 6.3.4. REST OF ASIA PACIFIC
  • 6.4. REST OF THE WORLD

COMPANY PROFILES

  • 7.1. ABBVIE
    • 7.1.1. INTRODUCTION
    • 7.1.2. ABBVIE PRODUCT PORTFOLIO
    • 7.1.3. ABBVIE RECENT ACTIVITIES
  • 7.2. AGENNIX
    • 7.2.1. INTRODUCTION
    • 7.2.2. AGENNIX PRODUCT PORTFOLIO
    • 7.2.3. AGENNIX RECENT ACTIVITIES
  • 7.3. AMGEN
    • 7.3.1. INTRODUCTION
    • 7.3.2. AMGEN PRODUCT PORTFOLIO
    • 7.3.3. AMGEN RECENT ACTIVITIES
  • 7.4. ASTRAZENECA
    • 7.4.1. INTRODUCTION
    • 7.4.2. ASTRAZENECA PRODUCT PORTFOLIO
    • 7.4.3. ASTRAZENECA RECENT ACTIVITIES
  • 7.5. BOEHRINGER INGELHEIM
    • 7.5.1. INTRODUCTION
    • 7.5.2. BOEHRINGER INGELHEIM PRODUCT PORTFOLIO
    • 7.5.3. BOEHRINGER INGELHEIM RECENT ACTIVITIES
  • 7.6. CELGENE
    • 7.6.1. INTRODUCTION
    • 7.6.2. CELGENE PRODUCT PORTFOLIO
    • 7.6.3. CELGENE RECENT ACTIVITIES
  • 7.7. CELLDEX
    • 7.7.1. INTRODUCTION
    • 7.7.2. CELLDEX PRODUCT PORTFOLIO
    • 7.7.3. CELLDEX RECENT ACTIVITIES
  • 7.8. EISAI
    • 7.8.1. INTRODUCTION
    • 7.8.2. EISAI PRODUCT PORTFOLIO
    • 7.8.3. EISAI RECENT ACTIVITIES
  • 7.9. ELI LILLY
    • 7.9.1. INTRODUCTION
    • 7.9.2. ELI LILLY PRODUCT PORTFOLIO
    • 7.9.3. ELI LILLY RECENT ACTIVITIES
  • 7.10. F. HOFFMANN-LA ROCHE
    • 7.10.1. INTRODUCTION
    • 7.10.2. F. HOFFMANN-LA ROCHE PRODUCT PORTFOLIO
    • 7.10.3. F. HOFFMANN-LA ROCHE RECENT ACTIVITIES
  • 7.11. GLAXOSMITHKLINE
    • 7.11.1. INTRODUCTION
    • 7.11.2. GLAXOSMITHKLINE PRODUCT PORTFOLIO
    • 7.11.3. GLAXOSMITHKLINE RECENT ACTIVITIES
  • 7.12. HELSINN
    • 7.12.1. INTRODUCTION
    • 7.12.2. HELSINN PRODUCT PORTFOLIO
    • 7.12.3. HELSINN RECENT ACTIVITIES
  • 7.13. IMCLONE
    • 7.13.1. INTRODUCTION
    • 7.13.2. IMCLONE PRODUCT PORTFOLIO
    • 7.13.3. IMCLONE RECENT ACTIVITIES
  • 7.14. MERCK SERONO
    • 7.14.1. INTRODUCTION
    • 7.14.2. MERCK SERONO PRODUCT PORTFOLIO
    • 7.14.3. MERCK SERONO RECENT ACTIVITIES
  • 7.15. NOVARTIS
    • 7.15.1. INTRODUCTION
    • 7.15.2. NOVARTIS PRODUCT PORTFOLIO
    • 7.15.3. NOVARTIS RECENT ACTIVITIES
  • 7.16. ONCOGENEX
    • 7.16.1. INTRODUCTION
    • 7.16.2. ONCOGENEX PRODUCT PORTFOLIO
    • 7.16.3. ONCOGENEX RECENT ACTIVITIES
  • 7.17. OSI PHARMACEUTICALS
    • 7.17.1. INTRODUCTION
    • 7.17.2. OSI PHARMACEUTICALS PRODUCT PORTFOLIO
    • 7.17.3. OSI PHARMACEUTICALS RECENT ACTIVITIES
  • 7.18. PEREGRINE
    • 7.18.1. INTRODUCTION
    • 7.18.2. PEREGRINE PRODUCT PORTFOLIO
    • 7.18.3. PEREGRINE RECENT ACTIVITIES
  • 7.19. PFIZER, INC.
    • 7.19.1. INTRODUCTION
    • 7.19.2. PFIZER, INC. PRODUCT PORTFOLIO
    • 7.19.3. PFIZER, INC. RECENT ACTIVITIES
  • 7.20. PIERRE FABRE
    • 7.20.1. INTRODUCTION
    • 7.20.2. PIERRE FABRE PRODUCT PORTFOLIO
    • 7.20.3. PIERRE FABRE RECENT ACTIVITIES
  • 7.21. QIAGEN
    • 7.21.1. INTRODUCTION
    • 7.21.2. QIAGEN PRODUCT PORTFOLIO
    • 7.21.3. QIAGEN RECENT ACTIVITIES
  • 7.22. ROCHE
    • 7.22.1. INTRODUCTION
    • 7.22.2. ROCHE PRODUCT PORTFOLIO
    • 7.22.3. ROCHE RECENT ACTIVITIES
  • 7.23. SANOFI
    • 7.23.1. INTRODUCTION
    • 7.23.2. SANOFI PRODUCT PORTFOLIO
    • 7.23.3. SANOFI RECENT ACTIVITIES
  • 7.24. SYNTA
    • 7.24.1. INTRODUCTION
    • 7.24.2. SYNTA PRODUCT PORTFOLIO
    • 7.24.3. SYNTA RECENT ACTIVITIES
  • 7.25. TELIK
    • 7.25.1. INTRODUCTION
    • 7.25.2. TELIK PRODUCT PORTFOLIO
    • 7.25.3. TELIK RECENT ACTIVITIES
  • 7.26. TEVA PHARMACEUTICAL
    • 7.26.1. INTRODUCTION
    • 7.26.2. TEVA PHARMACEUTICAL PRODUCT PORTFOLIO
    • 7.26.3. TEVA PHARMACEUTICAL RECENT ACTIVITIES

List of Tables

  • TABLE # 1 GLOBAL LUNG CANCER DRUGS MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
  • TABLE # 2 GLOBAL PLATINOL MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
  • TABLE # 3 GLOBAL TAXOL MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
  • TABLE # 4 GLOBAL GEMZAR MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
  • TABLE # 5 GLOBAL ALIMTA MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
  • TABLE # 6 GLOBAL IRESSA MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
  • TABLE # 7 GLOBAL HYCAMTIN MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
  • TABLE # 8 GLOBAL GILOTRIF MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
  • TABLE # 9 GLOBAL TAXOTERE MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
  • TABLE # 10 GLOBAL XALKORI MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
  • TABLE # 11 GLOBAL NAVELBINE MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
  • TABLE # 12 GLOBAL AVASTIN MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
  • TABLE # 13 GLOBAL TARCEVA MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
  • TABLE # 14 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
  • TABLE # 15 ABBVIE PRODUCT PORTFOLIO
  • TABLE # 16 ABBVIE RECENT ACTIVITIES
  • TABLE # 17 AGENNIX PRODUCT PORTFOLIO
  • TABLE # 18 AGENNIX RECENT ACTIVITIES
  • TABLE # 19 AMGEN PRODUCT PORTFOLIO
  • TABLE # 20 AMGEN RECENT ACTIVITIES
  • TABLE # 21 ASTRAZENECA PRODUCT PORTFOLIO
  • TABLE # 22 ASTRAZENECA RECENT ACTIVITIES
  • TABLE # 23 BOEHRINGER INGELHEIM PRODUCT PORTFOLIO
  • TABLE # 24 BOEHRINGER INGELHEIM RECENT ACTIVITIES
  • TABLE # 25 CELGENE PRODUCT PORTFOLIO
  • TABLE # 26 CELGENE RECENT ACTIVITIES
  • TABLE # 27 CELLDEX PRODUCT PORTFOLIO
  • TABLE # 28 CELLDEX RECENT ACTIVITIES
  • TABLE # 29 EISAI PRODUCT PORTFOLIO
  • TABLE # 30 EISAI RECENT ACTIVITIES
  • TABLE # 31 EISAIELI LILLY PRODUCT PORTFOLIO
  • TABLE # 32 EISAIELI LILLY RECENT ACTIVITIES
  • TABLE # 33 F. HOFFMANN-LA ROCHE PRODUCT PORTFOLIO
  • TABLE # 34 F. HOFFMANN-LA ROCHE RECENT ACTIVITIES
  • TABLE # 35 GLAXOSMITHKLINE PRODUCT PORTFOLIO
  • TABLE # 36 GLAXOSMITHKLINE RECENT ACTIVITIES
  • TABLE # 37 HELSINN PRODUCT PORTFOLIO
  • TABLE # 38 HELSINN RECENT ACTIVITIES
  • TABLE # 39 IMCLONE PRODUCT PORTFOLIO
  • TABLE # 40 IMCLONE RECENT ACTIVITIES
  • TABLE # 41 MERCK SERONO PRODUCT PORTFOLIO
  • TABLE # 42 MERCK SERONO RECENT ACTIVITIES
  • TABLE # 43 NOVARTIS PRODUCT PORTFOLIO
  • TABLE # 44 NOVARTIS RECENT ACTIVITIES
  • TABLE # 45 ONCOGENEX PRODUCT PORTFOLIO
  • TABLE # 46 ONCOGENEX RECENT ACTIVITIES
  • TABLE # 47 OSI PHARMACEUTICALS PRODUCT PORTFOLIO
  • TABLE # 48 OSI PHARMACEUTICALS RECENT ACTIVITIES
  • TABLE # 49 PEREGRINE PRODUCT PORTFOLIO
  • TABLE # 50 PEREGRINE RECENT ACTIVITIES
  • TABLE # 51 PFIZER, INC. PRODUCT PORTFOLIO
  • TABLE # 52 PFIZER, INC. RECENT ACTIVITIES
  • TABLE # 53 PIERRE FABRE PRODUCT PORTFOLIO
  • TABLE # 54 PIERRE FABRE RECENT ACTIVITIES
  • TABLE # 55 QIAGEN PRODUCT PORTFOLIO
  • TABLE # 56 QIAGEN RECENT ACTIVITIES
  • TABLE # 57 ROCHE PRODUCT PORTFOLIO
  • TABLE # 58 ROCHE RECENT ACTIVITIES
  • TABLE # 59 SANOFI PRODUCT PORTFOLIO
  • TABLE # 60 SANOFI RECENT ACTIVITIES
  • TABLE # 61 SYNTA PRODUCT PORTFOLIO
  • TABLE # 62 SYNTA RECENT ACTIVITIES
  • TABLE # 63 TELIK PRODUCT PORTFOLIO
  • TABLE # 64 TELIK RECENT ACTIVITIES
  • TABLE # 65 TEVA PHARMACEUTICAL PRODUCT PORTFOLIO
  • TABLE # 66 TEVA PHARMACEUTICAL RECENT ACTIVITIES

List of Figures

  • FIGURE # 1 NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2015-2021
  • FIGURE # 2 UNITED STATES MARKET RESEARCH AND ANALYSIS, 2015-2021
  • FIGURE # 3 CANADA MARKET RESEARCH AND ANALYSIS, 2015-2021
  • FIGURE # 4 REST OF NORTH AMERICA MARKET RESEARCH AND ANALYSIS, 2015-2021
  • FIGURE # 5 EUROPE MARKET RESEARCH AND ANALYSIS, 2015-2021
  • FIGURE # 6 UK MARKET RESEARCH AND ANALYSIS, 2015-2021

FIGURE #7 GERMANY MARKET RESEARCH AND ANALYSIS, 2015-2021

FIGURE #8 SPAIN MARKET RESEARCH AND ANALYSIS, 2015-2021

  • FIGURE # 9 FRANCE MARKET RESEARCH AND ANALYSIS, 2015-2021
  • FIGURE # 10 SPAIN MARKET RESEARCH AND ANALYSIS, 2015-2021
  • FIGURE # 11 ITALY MARKET RESEARCH AND ANALYSIS, 2015-2021
  • FIGURE # 12 REST OF EUROPE MARKET RESEARCH AND ANALYSIS, 2015-2021
  • FIGURE # 13 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2015-2021
  • FIGURE # 14 INDIA MARKET RESEARCH AND ANALYSIS, 2015-2021
  • FIGURE # 15 CHINA MARKET RESEARCH AND ANALYSIS, 2015-2021
  • FIGURE # 16 JAPAN MARKET RESEARCH AND ANALYSIS, 2015-2021
  • FIGURE # 17 ROPAC MARKET RESEARCH AND ANALYSIS, 2015-2021
  • FIGURE # 18 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2015-2021
Back to Top